Get started
Lexicon Pharmaceuticals, Inc.LL

Lexicon Pharmaceuticals, Inc.

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Forecast Seasonals Options

LXRX trade ideas

$LXRX is gonna fall todayPupm&Dump trading strategy idea. $LXRX is rising without clear preconditions today. The demand for shares of the company looks lower than the supply. This and other conditions can cause a fall in the share price today. So I opened a short position from $2,50; stop-loss — $2,84; take-profit — $2,16; Do not view this idea as a recommendation for trading or investing. It is published only to introduce my own vision. Always do your own analysis before making deals. When you use any materials, do not rely on blind trust. You should remember that isolated deals do not give systematic profit, so trade/invest using a developed strategy. If you like my content, you can subscribe to the news and receive my fresh ideas. Thanks for being with me!
NASDAQ:LXRXShort
by KozakHlib
1
$LXRX Fill The Gap And Go Or Will It Breakdown?LXRX is a penny stock that has performed well over the last few weeks but looking at the chart, shares are trading within the gap zone. Volume this week compared to previous weeks is lower. Is that a concern or just a slow week? "Shares of LXRX stock have been on a tear for around a month. This was ever since terminating its partnership agreement with Sanofi. The termination gave Lexicon full control over its diabetes product Zynquista and in addition to that, Sanofi is going to pay the company as much as $260 million as a parting shot...The company will be conducting poster presentations of its XERMELO therapy this week at the North American Neuroendocrine Tumor Society Annual Multidisciplinary NET Medical Symposium." * About LXRX Lexicon Pharmaceuticals is a biopharmaceutical company that uses mouse genetics to discover the function of genes and find promising drug targets. Lexicon then designs and develops drugs for these targets, which cover a broad spectrum of therapeutic areas. Following a restructuring in January 2014, Lexicon focused efforts on two drugs: sotagliflozin in diabetes, which is partnered with Sanofi, and Xermelo (telotristat etiprate) in carcinoid syndrome, which is partnered with Ipsen outside the U.S. Early-stage programs include SGLT1 inhibitor LX2761 and neuropathic pain drug LX9211. *SOURCE: Are Penny Stocks Worth It? 3 Up Big In October
N
by PennyStocks101
LXRX - Bullish But Risky Move. Pullback ComingLexicon Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. It drug candidates include XERMELO, Sotagliflozin, LX2761, and LX9211. The company was founded by Brian P. Zambrowicz and Arthur T. Sands on July 7, 1995 and is headquartered in The Woodlands, TX. SHORT INTEREST 7.74M 08/15/19 P/E Current -1.51 P/E Ratio (with extraordinary items) -2.05 Average Recommendation: OVERWEIGHT Average Target Price: 8.00
N
by DEXWireNews
1